1 Parapneumonic effusions related to *Streptococcus pneumoniae*: serotype and disease

- 2 severity trends
- 3 Catherine Hyams MB PhD, Academic Respiratory Unit and Bristol Vaccine Centre,
- 4 University of Bristol, Bristol, UK. ORCID: 0000-0003-3923-1773
- 5 David T Arnold PhD, Academic Respiratory Unit, University of Bristol, Bristol, UK. ORCID
- 6 0000-0003-3158-7740
- 7 Robyn Heath, MA. Vaccine and Testing Research Team, Clinical Research Facility, St
- 8 Michael's Hill, Bristol Royal Infirmary, Bristol, United Kingdom
- 9 Zahin Amin-Chowdhury MSc. National Infection Service, UKHSA, London, United
- 10 Kingdom
- 11 David Hettle MBChB. Microbiology Services Bristol, Bristol Royal Infirmary and North
- 12 Bristol NHS Trust, Bristol, United Kingdom. ORCID: 0000-0002-7606-986X
- 13 Gabriella Ruffino MBChB, Academic Respiratory Unit and Bristol Vaccine Centre,
- 14 University of Bristol, Bristol, UK. ORCID: 0000-0002-1549-9364
- 15 Paul North BSc, Microbiology Services Bristol, Bristol Royal Infirmary and North Bristol
- 16 NHS Trust, Bristol, United Kingdom.
- 17 Charli Grimes BSc, Academic Respiratory Unit and Bristol Vaccine Centre, University of
- 18 Bristol, Bristol, UK. ORCID: 0000-0002-0171-0704
- 19 Norman K Fry PhD, National Infection Service, UKHSA, London, United Kingdom.
- 20 ORCID: 0000-0003-4862-6507
- 21 Philip Williams PhD, Microbiology Services Bristol, Bristol Royal Infirmary and North
- 22 Bristol NHS Trust, Bristol, United Kingdom.
- 23 Leon Danon PhD, Engineering Mathematics, University of Bristol, Bristol, United Kingdom
- 24 O Martin Williams PhD, Microbiology Services Bristol, Bristol Royal Infirmary and North
- 25 Bristol NHS Trust, Bristol, United Kingdom.
- 26 Shamez Ladhani PhD, National Infection Service, UKHSA, London, United Kingdom.
- 27 ORCID: 0000-0002-0856-2476
- 28 Adam Finn PhD, Bristol Vaccine Centre, University of Bristol, Bristol, UK. ORCID: 0000-
- 29 0003-1756-5668
- 30 Nick A Maskell MD, Academic Respiratory Unit, University of Bristol, Bristol, UK. ORCID:
- 31 0000-0002-1276-6500
- 32

```
    33 Corresponding address: Dr Catherine Hyams, MBBS BSc(Hons) PhD MRCP
    34 Academic Respiratory Unit, Learning & Research Building,
```

35 36		Southmead Hospital, Bristol, BS10 5NB catherine.hyams@bristol.ac.uk
37	Descriptor:	9.31 Pleural Diseases/Mesothelioma
38	Running head:	Pneumococcal related parapneumonic effusions
39	Keywords:	Streptococcus pneumoniae; Empyema; Pleural Effusion
40		
41	Author Contributions:	CH, DA, AF, OMW and NM generated the research questions
42		and analysis plan. CH, RH, DH, GF, DA, PN, PW, ZAC
43		collected data. CH and DH verified the data. CH, DA, RH, AF
44		and NM undertook the data analysis. AF, OMW and NM
45		provided oversight of the research. AF and CH verified the
46		data. All authors contributed to the preparation of the
47		manuscript and its revision for publication and had
48		responsibility for the decision to publish.
49		
50	Funding: CH was f	unded by the National Institute for Health Research [NIHR
51	Academic (Clinical Fellowship (ACF-2015-25-002). DTA was funded by an
52	NIHR Doc	toral Research Fellowship (DRF-2018-11-ST2-065). The views
53	expressed a	re those of the author(s) and not necessarily those of the NIHR or
54	the Departn	nent of Health and Social Care.
55		
56	Declarations: CH is Princ	ipal Investigator of the AvonCAP study which is an investigator-
57	led Univers	ity of Bristol study funded by Pfizer. AF is a member of the Joint
58	Committee	on Vaccination and Immunization (JCVI) and chair of the World
59	Health Org	anization European Technical Advisory Group of Experts on
60	Immunizati	on (ETAGE) committee. In addition to receiving funding from
61	Pfizer as Ch	hief Investigator of this study, he leads another project investigating
62	transmission	n of respiratory bacteria in families jointly funded by Pfizer and the
63	Gates Foun	dation. The other authors have no relevant conflicts of interest to
64	declare.	
65		
66	Word Count: 2938	3

67 ABSTRACT

68 **Rationale**

- 69 Streptococcus pneumoniae epidemiology is changing in response to vaccination and some
- 70 data suggest empyema incidence is increasing. However, differences exist between UK and
- 71 USA studies. We describe trends in the clinical phenotype of adult pneumococcal pleural
- infection, including simple parapneumonic effusions (SPE) in the pneumococcal conjugate
- 73 vaccination (PCV) era.

74 **Objectives:**

- 75 To determine whether there were differences in pneumococcal disease presentation and
- 76 severity associated with pleural infection.

77 Methods

- A retrospective cohort study, all adults ≥ 16 years admitted to three large UK hospitals, 2006-
- 79 2018 with pneumococcal disease. 2477 invasive pneumococcal cases were identified: 459
- 80 SPE and 100 pleural infection cases. Medical records were reviewed for each clinical

episode. Serotype data were obtained from the UK Health Security Agency national referencelaboratory.

83 **Results**

84 Incidence increased over time, including non-PCV-serotype disease. PCV7-serotype disease

85 declined following paediatric PCV7 introduction, but the effect of PCV13 was less apparent

- as disease caused by the additional six serotypes plateaued with serotypes 1 and 3 causing
- such parapneumonic effusions from 2011 onwards.
- 88 Patients with pleural infection had a median survival 468 days (95% CI 340-590) in, versus
- 89 286 days (95% CI 274-335) in those with SPE. Pleural infection associated with frank pus

90	had lower 90-day mortalit	than pleural infection	without pus (0% vers	us 29%, <i>P</i> <0.0001).
----	---------------------------	------------------------	----------------------	----------------------------

- 90-day mortality could be predicted by baseline increased RAPID (Renal, Age, Purulence,
- 92 Infection source, and Dietary factors) score (HR15.01, 95% CI 1.24-40.06, P=0.049).

93 **Conclusions**

- 94 Pneumococcal infection continues to cause severe disease despite the introduction of PCVs.
- 95 The predominance of serotype 1 and 3 in this adult UK cohort is in keeping with previous
- 96 studies in paediatric and non-UK studies. Rising non-PCV serotype disease and limited
- 97 impact of PCV13 on cases caused by serotypes 1 and 3 offset the reductions in adult
- 98 pneumococcal parapneumonic effusion disease burden observed following introduction of the
- 99 childhood PCV7 programme.

101 INTRODUCTION

102	Streptococcus pneumoniae remains the leading bacterial cause of community-acquired
103	pneumonia (CAP), despite vaccine deployment. A dose of PneumoVax® (unconjugated 23-
104	valent polysaccharide vaccine, PPV23) is offered to all adults from age 65 years in the UK
105	and \geq 2-year-olds with at least one clinical risk factor for pneumococcal disease also receive
106	this vaccine (1). The 7-valent pneumococcal conjugate vaccine (PCV) (PCV7) was
107	introduced into the UK childhood vaccination programme in 2006 on a 2 priming dose
108	schedule with a booster following the first birthday (2+1) and subsequently replaced in April
109	2010 with a 13-valent PCV (PCV13). The schedule was modified to 1+1 in 2020. Several
110	USA studies have shown that PCV introduction resulted in a significant reduction in both
111	carriage and invasive pneumococcal disease (IPD) due to vaccine serotypes, especially in
112	children (2, 3) although an increase in pneumococcal empyema cases in children has been
113	reported (4) and the effect of paediatric PCV deployment on adult disease phenotype is
114	debated (5). By 2016/17, UK surveillance demonstrated that PCV7 serotype disease in
115	children had virtually disappeared, with significant reduction in PCV7 disease burden in
116	adults. In contrast, while PCV13 serotype disease incidence has not disappeared across all
117	age groups, but plateaued, with a remaining residual incidence of 7.97 per 100,000 across all
118	age groups. There has also been an increase in disease attributable to non-PCV13 serotypes,
119	especially in the elderly, which has reduced overall disease reduction resulting from vaccine
120	introduction (6-8). Evidence from a large pneumococcal pneumonia patient cohort in
121	Nottingham, UK suggests that, aside from age, residential care status and some
122	comorbidities, there are relatively few differences between patients with disease caused by
123	PCV13 and those with non-PCV13 serotype infections (9).

124

125	Approximately 15-20% hospitalised pneumococcal CAP cases are associated with a pleural
126	effusion (10, 11) and 6% with empyema (10, 12). However, recent evidence suggests that
127	incidence of pneumococcal empyema has increased following paediatric PCV deployment,
128	especially in adults aged >65 years, possibly due to serotype 1 emergence (13). Thus,
129	vaccine-driven serotype replacement may be leading to changes in pneumococcal disease
130	phenotype and severity. This is a concern as morbidity and mortality associated with simple
131	parapneumonic effusion (SPE) are higher than with uncomplicated pneumonia (14).
132	
133	Here we present the largest cohort of patients with a single-organism pleural infection,
134	encompassing SPE and pleural infection (complex parapneumonic effusion (CPE) or
135	empyema) attributable to pneumococcus, in a single-centre observational study covering
136	thirteen years during which PCVs were introduced into the UK paediatric vaccination
137	programme. We sought to determine whether there were any differences in pneumococcal
138	disease presentation and severity associated with pleural infection, given concerns
139	surrounding changing pneumococcal serotype distribution.

140 MATERIALS AND METHODS

141 **Study Subjects**

- 142 Patients aged ≥ 16 years admitted to all three hospitals providing emergency care in Bristol
- 143 and Bath (University Hospitals Bristol and Weston, North Bristol and The Royal United
- 144 Hospital NHS Trusts) between January 2006 and December 2018, with a confirmed
- 145 microbiological diagnosis of pneumococcal infection were eligible for this study. This study
- 146 was approved by the Health Research Authority, UK (IRAS 265437).

147

148 Study Design

149 A retrospective cohort study at three large NHS hospitals in the UK.

150

151 Methods

152 Study-eligible cases were identified retrospectively by searching the Laboratory Information

153 Management System (LIMS) database (Clinisys WinPath Enterprise). S. pneumoniae was

- 154 confirmed on culture from sterile-site sampling at a central laboratory using standard
- 155 microbiological techniques combined with API®-20 Strep (BioMérieux, UK) or MALDI-
- 156 TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry (Bruker,
- 157 UK) (15). A positive pneumococcal urinary-antigen test (BinaxNOW®, Alere, UK) was also
- 158 considered confirmative of pneumococcal infection. Any patient with pleural fluid which
- 159 cultured a single-organism which was not pneumococcus was excluded from this cohort;
- 160 although, multi-organism pleural infection including pneumococcus was included.

- 162 Confirmed cases were linked with the UK Health Security Agency (UKHSA) national
- 163 reference laboratory to obtain serotype data (16) which were collected separately from
- 164 clinical data to avoid any risk of bias in data collection. Pneumococcal serotypes were

165 grouped by PCV (PCV7; PCV13-7 representing the additional 6 serotypes in PCV13; and

- 166 PCV13) or as non-PCV (Supplementary Data 1).
- 167
- 168 Patients with pneumococcal infection and a pleural effusion on radiology were either

169 classified as:

- 170 (1) pleural infection: if pleural fluid was pus; bacterial culture positive pleural fluid; an
- 171 effusion relating to a current pneumonia episode which necessitated definitive drainage (e.g.

172 thoracic surgery); or, there was an exudative effusion with pH \leq 7.2; or,

- 173 (2) SPE: an exudative effusion not classified as pleural infection in a patient with a clinical
- 174 and/or radiological diagnosis of pneumonia.
- 175
- 176 Patients' clinical records were reviewed at each hospital and data, including clinical
- 177 outcomes, recorded. The vaccination status of each patient was established from
- 178 electronically linked GP records (15). The CURB65 severity score on admission was
- 179 calculated for each clinical episode (17). Patients with pleural infection had a RAPID (Renal,
- 180 Age, Purulence, Infection source, and Dietary factors) score calculated (18), which has been
- 181 validated to stratify adults with pleural infection according to increasing risk of mortality

182 (19).

183

184 Analysis

185	Patient data are reported as medians and interquartile ranges (IQR) for continuous variables.
186	Categorical variables are presented as counts and percentages. Baseline characteristics and
187	comorbid risk factors for SPE and pleural infection were compared using Fisher's exact tests
188	for categorical variables, and the Mann-Whitney U-test for non-parametric continuous
189	variables. The Kaplan-Meier (KM) method and Cox proportional hazard regression model
190	were used for calculation of survival at 30-, 90- and 365-days following first positive
191	pneumococcal microbiological test. Proportional hazard assumptions were tested by visual
192	assessment of the KM survival curve, log(-log) plots and Schoenfeld residuals. Survival
193	differences were analyzed using the log-rank test. Statistical analysis was performed using
194	SPSS, version 28.0 (New York, IBM). Graphs were generated in GraphPad PRISM, version

195 9.0.

196 **RESULTS**

197	2657 IPD episodes were identified, of which 2447 were respiratory infections: 1888
198	pneumonia cases, 459 SPE and 100 cases of pleural infection (Figure 1). 283/559 (51%)
199	cases with parapneumonic effusion had S. pneumoniae confirmed on blood culture, and in 42
200	cases pneumococcus was isolated from pleural fluid. In total, 282/559 (50%) were male with
201	a median age of 68y (IQR 50-78) (Table 1, Supplementary Data 2). Pre-existing cardiac and
202	respiratory disease was common in patients with parapneumonic effusions. Patients with
203	pleural infection were younger than those with SPE (median ages 55 vs 69y respectively,
204	P < 0.001), and were more likely to have history of alcohol misuse and/or intravenous drug
205	usage ($P < 0.05$) and less likely to develop acute renal failure ($P < 0.05$). On presentation to
206	hospital, neither clinical observations nor CURB65 score differed significantly between
207	patients with SPE and pleural infection ($P > 0.05$); in contrast, patients with pleural infection
208	had both a significantly greater neutrophilia (P <0.01) and more elevated CRP levels
209	(P<0.001) (Table 1, Supplementary Data 2 and 3).

210

211 Annual incidence of S. pneumoniae parapneumonic effusions increased throughout the study 212 period (Figure 2A). There was a 33% and 34% increase in unplanned hospital admissions and 213 microbiological testing between 2006 and 2018 (Supplementary Data 4, indicating relative 214 increase in hospital workload was not equivalent to the increase in disease incidence. The age 215 of patients admitted throughout the study did not show any apparent trend (Supplementary 216 Data 5). In 38% cases serotype was available, of which overall 52% were attributable to a 217 PCV13 serotype while only 8% were caused by a non-vaccine serotype. Over the study 218 period, there was an absolute and proportional decrease in disease caused by PCV7 serotypes. 219 All parapneumonic effusions caused by a PCV7 serotype after 2011 were SPE (serotypes 14 220 and 19F), with no pleural infections caused by a PCV7 serotype after 2011. PCV13-7 disease

221	showed an initial rise, followed by a fall after PCV13 introduction with a gradual rise in
222	disease over the last 5 study years (Figure 2B). Following the introduction of PCV13 in 2010,
223	the only PCV13-7 serotypes that caused pneumococcal pleural infections were 1 and 3: 2
224	(17% of serotype known disease) and 3 (25%) pre-2010 pleural infection cases versus 9
225	(30%) and 7 (23%) post-2010 pleural infection cases due to serotype 1 and 3 respectively.
226	Serotype 1 affected younger patients than serotype 3, but was associated with increased rates
227	of renal failure (77% versus 43%, P=0.007), higher RAPID severity group (high RAPID
228	severity group 36% versus 17%, P=0.024) and a trend towards higher loculation rates (23%
229	versus 10%, $P=0.205$) than seen in patients with serotype 3 parapneumonic effusions (Table
230	2).
221	

231

232	Overall, 19% patients with pneumococcal parapneumonic effusions died within 90-days of
233	presentation (Table 1, Supplementary Table 6). Patients with pleural infections had higher
234	survival rates than those with SPE at 30-, 90- and 365-days (P<0.01) (Figure 3A). Median
235	survival was 468 days (340-590 days, 95% CI) in patients with pleural infection, vs 286 (274-
236	335 days, 95% CI) in those with SPE. In total, 59/100 (59%) pleural infection patients had
237	pus and these patients had improved 30-, 90-, and 365-day mortality compared to those
238	without pus; in contrast, loculation was associated with reduced 30-, 90- and 365-day
239	mortality (Table 4). Surgical management was associated with improved prognosis: no deaths
240	occurred within 1-year of presentation compared to 24% mortality in patients with pleural
241	infection who did not undergo surgery. Patients undergoing thoracic surgery were younger
242	than those who did not (median age 45 years, IQR40-52 versus 66 years, IQR53-78).

243

- 244 The mortality rate among patients with pleural infection increased alongside RAPID score
- severity at 30-, 90- and 365-days (Figure 3B, Table 3), and a high RAPID score was
- associated with a median survival of 56 days (20-154 days, 95% CI). Proportional hazards
- 247 regression analysis confirmed that more severe RAPID group was associated with increased
- 248 90-day (*P*=0.049, 95% CI 1.24-40.06) and 365-day mortality (*P*=0.034, 95% CI 1.09-51.2)
- 249 (Table 4).
- 250

251 **DISCUSSION**

252	This observational cohort study, with data from a 13-year period spanning PCV introduction
253	into the UK childhood vaccination programme, shows an increasing incidence of adult
254	pneumococcal parapneumonic effusions. An increasing incidence of pneumococcal disease
255	has also been reported by other UK studies (9, 16, 20, 21), with Pick et al reporting incidence
256	of pneumococcal pneumonia of 32.2 and 48.2 per 100,000 population in 2013 and 2018
257	respectively (9). Using previously published estimates that up to 20% of adults hospitalised
258	with pneumococcal pneumonia develop a pleural effusion (10, 11), estimates of
259	parapneumonic effusion incidence from that study would be 6.4 and 9.6 in 2013 and 2018,
260	which are similar to the incidence rates of 5.0 and 9.8 observed in the same years in this
261	study. Recent national epidemiological studies of pleural infection from North America also
262	show significant increases in pleural infection rates both in children (22) and adults (23).
263	Likewise, a Danish study from 1997-2001, showed steadily rising pleural infection rates in
264	the elderly (24) and a UK study showed annual rises in adult pleural infections from 2008-17
265	(25), most marked in over 60-year-old individuals with a 194% increase over the decade.
266	Both overall admissions and microbiological testing at the study hospitals increased
267	progressively during our study period, but not as much as disease incidence, suggesting this
268	did not solely account for the increasing incidence observed. Whilst the study period
269	encompassed a time when the UK vaccination programme changed, there was also an
270	expanding total and older adult population in Bath and Bristol. Furthermore, there may have
271	been changes in patient or physician treatment preferences, including threshold for referral to
272	secondary care, diagnostic testing and treatment which may have impacted the incidence of
273	disease estimated throughout this study (26).

274

275	The introduction of PCV7 into the UK childhood vaccination programme in 2006 was
276	followed by a decrease in adult pneumococcal pleural effusions attributable to PCV7 vaccine
277	serotypes in this study. Notably, all parapneumonic effusions due to PCV7 serotypes after
278	2011 were SPE and due to serotypes 14 and 19F, with no cases of pleural infection. However,
279	PCV13 introduction in 2010 did not result in such a marked indirect reduction in disease
280	caused by the additional six serotypes in PCV13 due to the persistence of serotype 1 or 3
281	disease. This partially aligns with national serotype trends, showing reductions in both PCV7
282	serotype and serotype 1 adult IPD incidence (6), and both serotypes are prevalent in studies
283	of pleural infection in children (27). In the UK, large reductions in vaccine-serotype adult
284	IPD were offset by increases in non-PCV13 IPD (6, 16, 20), a trend also apparent in this
285	patient cohort, with non-PCV13 disease increasing from 30% to 60% of known serotype
286	disease. Pick et al showed an increase in non-PCV13 serotype pneumococcal pneumonia
287	from 2014/15 onwards (9) as well as an overall increase in PCV13-7 serotype disease, in
288	contrast to trends reported in this study. These are the first data on serotype trends in adult
289	pneumococcal pleural disease since paediatric PCV introduction in the UK.
290	

292 colonisation, the number of episodes of invasive disease per colonisation event, morality and

Serotype affects pneumococcal resistance to innate immunity, duration of nasopharyngeal

disease severity (28-30). The two PCV13-7 serotypes which continued to cause

291

294 pneumococcal pleural infection following PCV13 introduction are notable serotypes as they

295 have unusual polysaccharide capsules. Serotype 1 expresses a zwitterionic and structurally

diverse polysaccharide capsule, which uniquely may act as a T-cell dependent antigen (31).

297 This serotype rarely causes asymptomatic nasopharyngeal colonization but is a commonly

- isolated in IPD (28), and frequently causes invasive pneumonia (32). Studies suggests
- serotype 1 is more likely to be identified in young patients, and in some studies it is the most

300	frequent cause of pneumococcal pleural infection, with increasing pleural infection incidence
301	attributable to this serotype (11, 13). In contrast, the serotype 3 polysaccharide capsule is
302	large, resulting in a highly mucoid appearance, and is one of a few capsules produced by
303	synthase-mediated synthesis (33). Serotype 3 also causes considerable disease burden (11,
304	27) being the most common overall cause of pneumonia in the USA (34), is highly invasive
305	(28) and is associated with increased mortality (29). Distinct lineages exist within serotype 3
306	clonal complex 180, and recent clade distributions shift has led to the emergence and
307	expansion of clade II (35, 36), which now represents 50% serotype 3 IPD in the UK (37). We
308	could not determine serotype 3 clade grouping in this analysis, but clade II emergence may,
309	at least in part, explain serotype 3 disease persistence.
310	
311	Overall, pre-existing medical conditions were commonly present amongst adults with
312	pneumococcal parapneumonic effusions, although the median patient age was lower than that
313	seen in other cohorts of parapneumonic effusions (12, 25). Uniquely, this cohort of
314	parapneumonic effusion cases were all attributable to pneumococcal infection, which may
315	cause the condition in younger patients than other pathogens (25, 38). Despite this, the
316	burden of pre-existing medical comorbidity was equivalent: both SPE and pleural infection
317	patients had significant cardiac (44%) and respiratory (43%) conditions predominating. A
318	large systematic review found that 72% of patients with pleural infection had at least one
319	significant comorbidity, with high levels of pre-existing cardiac (19%) and respiratory (20%)
320	diseases (38). Excessive alcohol consumption was significantly more common among pleural
321	infection cases, in line with other published cohort studies (14). Alcohol abuse may
322	predispose to the development of pleural infection through its general immunosuppressive
323	effect in addition to associated increases in risk of aspiration and delayed presentation to

324 medical services (12).

325

326	As shown in the initial validation and subsequent cohort studies of the RAPID score (18, 19),
327	a high score was strongly associated with the risk of mortality by 3-months. Study patients in
328	the low-risk group had a 3% (95% C.I 0.7 to 15%) risk of 90-day mortality compared to 57%
329	(95% C.I. 28% to 82% P <0.01), for those with a high risk score, while there was much less
330	difference in survival between those in low and medium RAPID groups, as reported by others
331	(19, 39). There was a positive association between pleural fluid purulence and survival: this
332	relationship has been demonstrated in cohorts that were not restricted by causative organism,
333	suggesting it is disease and not pathogen specific (18). Anecdotal report findings suggest
334	effusions comprised of frank pus tend to be non-loculated and therefore more readily drained.

335

336 Interestingly, our data suggests that patients with pneumococcal pleural infection have 337 improved survival up to one year compared to patients with pneumococcal SPE. It should be 338 noted that up to 30% of effusions are known to have more than one aetiology (40), with many 339 having a cardiac or renal component. It therefore can be difficult to determine the full 340 aetiology of a pleural effusion, and pneumococcal SPEs may be often due to dual aetiology 341 e.g. infection, causing atrial fibrillation and cardiac failure. In this cohort, pre-existing cardiac 342 disease and bilateral effusions were more common in patients with SPE. Previous data 343 suggests individuals with pneumonia and cardiac failure have higher mortality rates (41), and 344 bilateral effusions are associated with worse outcomes (41, 42). Hence, whilst some effusions 345 reflect more severe lung inflammation, others may reflect concomitant comorbidity in the 346 host; either factor can account for worse outcome and may explain this finding in our cohort. 347 Further, the high proportion of patients undergoing surgical intervention, which is associated

with improved outcomes (43, 44), may have improved patient survival in the pleural infectionpatients.

350

351	This study identified patients with pneumococcal infection and parapneumonic effusions
352	within a defined geographical area, covering a population of approximately one million
353	adults, and encompassed 3 large hospitals with 100,000 unplanned adult admissions annually.
354	One of these hospitals is the regional thoracic surgery centre, whilst another has a specialist
355	pleural disease service, possibly increasing the accuracy of the clinical data presented here.
356	We captured disease and serotype trends over 13 years, spanning PCV introduction. By
357	linking with the UKHSA national reference laboratory we were able to report serotype where
358	it was available. Importantly, the epidemiological data were supported with detailed clinical
359	information for individual patients, including short- and long-term outcomes. However, this
360	study also has limitations. This is a retrospective observational study; therefore, only
361	information documented in clinical records could be included and patients were managed at
362	the discretion of individual physicians. As a regional study, the findings here may not be
363	representative of other populations; although, our serotype trends are comparable to other UK
364	national and regional reports. We included patients who tested positive for pneumococcus
365	using the BinaxNOW® urinary antigen test, which has a known sensitivity of 65% and
366	prolonged positive test result after exposure to pneumococcus (45). Lastly, different
367	methodologies were used to identify pneumococcal serotypes during the study period; whole
368	genomic sequencing was only routinely used by UKHSA from October 2017, and therefore
369	earlier isolates did not have this performed.

370

- 371 Overall, we found an increasing incidence of pneumococcal parapneumonic effusion in this
- 372 UK population. The proportion of disease attributable to PCV7 serotypes fell after 2006,
- 373 when the PCV7 vaccine was introduced into the UK childhood vaccination programme;
- 374 importantly, no cases of PCV7 pleural infection occurred in adults after 2011. However,
- disease attributable serotypes 1 and 3 did not show decline following PCV13 vaccine rollout.
- 376 Further research is needed to determine if *S. pneumoniae* serotype is predictive of mortality
- 377 risk in adults with pneumococcal parapneumonic effusions.

378 ACKNOWLEDGEMENTS

- 379 The authors would like to acknowledge the research teams at The Royal United, North
- 380 Bristol and University Hospitals of Bristol and Weston NHS Trusts.
- 381

382 DATA SHARING

- 383 The data used in this study are sensitive and cannot be made publicly available without
- 384 breaching patient confidentiality rules. Therefore, individual participant data and a data
- 385 dictionary is not available to other researchers.

386 **REFERENCES**

387 1. UKHSA. Pneumococcal: The green book.2020. p. 1-13.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak
 PR, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of
 protein-polysaccharide conjugate vaccine. *New England Journal of Medicine* 2003;348(18):1737 1746.

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen
 HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive
 pneumococcal disease incidence and mortality. *Clinical Infectious Diseases* 2014;59(8):1066-1073.

Kelly MM, Coller RJ, Kohler JE, Zhao Q, Sklansky DJ, Shadman KA, Thurber A, Barreda CB,
Edmonson MB. Trends in hospital treatment of empyema in children in the united states. *The Journal of Pediatrics* 2018;202:245-251.e241.

398 5. Weinberger DM, Harboe ZB, Shapiro ED. Developing better pneumococcal vaccines for adults. *JAMA Internal Medicine* 2017;177(3):303-304.

400 6. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, 401 Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in 402 england and wales, 2000-2013;17: A prospective national observational cohort study. *The Lancet* 403 *Infectious Diseases* 2018;18(4):441-451.

4047.Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype405replacement 4 years after seven-valent pneumococcal conjugate vaccination in england and wales:406An observational cohort study. Lancet Infect Dis 2011;11(10):760-768.

4078.Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-408valent pneumococcal conjugate vaccine on invasive pneumococcal disease in england and wales 4409years after its introduction: An observational cohort study. Lancet Infect Dis 2015;15(5):535-543.

Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, Baskaran V, Edwards-Pritchard
RC, Sheppard C, Eletu SD, et al. Pneumococcal serotype trends, surveillance and risk factors in uk
adult pneumonia, 2013–18. *Thorax* 2020;75(1):38.

Vallés X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, Torres A. Hospitalized
 community-acquired pneumonia due to streptococcus pneumoniae: Has resistance to antibiotics
 decreased? *Chest* 2006;130(3):800-806.

Cillóniz C, Ewig S, Polverino E, Muñoz-Almagro C, Marco F, Gabarrús A, Menéndez R, Mensa
J, Torres A. Pulmonary complications of pneumococcal community-acquired pneumonia: Incidence,
predictors, and outcomes. *Clinical Microbiology and Infection* 2012;18(11):1134-1142.

419 12. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for 420 complicated parapneumonic effusion and empyema on presentation to hospital with community-421 acquired pneumonia. *Thorax* 2009;64(7):592.

422 13. Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A,
423 Knol MJ. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2–6 years
424 after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period,
425 the netherlands. *Vaccine* 2016;34(8):1077-1085.

426 14. Falguera M, Carratalà J, Bielsa S, García-Vidal C, Ruiz-González A, Chica I, Gudiol F, Porcel JM.
427 Predictive factors, microbiology and outcome of patients with parapneumonic effusion. *European*428 *Respiratory Journal* 2011;38(5):1173.

Hyams C, Amin-Chowdhury Z, Fry NK, North P, Finn A, Judge A, Ladhani SN, Williams OM.
Streptococcus pneumoniae septic arthritis in adults in bristol and bath, united kingdom, 2006–2018:
A 13-year retrospective observational cohort study. *Emerging Microbes & Infections*2021;10(1):1369-1377.

433 16. Amin-Chowdhury Z, Collins S, Sheppard C, Litt D, Fry NK, Andrews N, Ladhani SN. 434 Characteristics of invasive pneumococcal disease caused by emerging serotypes after the

435 introduction of the 13-valent pneumococcal conjugate vaccine in england: A prospective 436 observational cohort study, 2014–2018. *Clinical Infectious Diseases* 2020.

Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA,
Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: An
international derivation and validation study. *Thorax* 2003;58(5):377.

Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (rapid)
to identify those at risk for poor outcome at presentation in patients with pleural infection. *Chest*2014;145(4):848-855.

Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I,
Heinink R, West A, et al. Prospective validation of the rapid clinical risk prediction score in adult
patients with pleural infection: The pilot study. *European Respiratory Journal* 2020:2000130.

446 20. Houseman C, Hughes GJ, Chapman KE, Wilson D, Gorton R. Increased invasive pneumococcal 447 disease, north east england, uk. *Emerging infectious diseases* 2017;23(1):122-126.

448 21. Abram SGF, Alvand A, Judge A, Beard DJ, Price AJ. Mortality and adverse joint outcomes 449 following septic arthritis of the native knee: A longitudinal cohort study of patients receiving 450 arthroscopic washout. *The Lancet Infectious Diseases* 2020;20(3):341-349.

451 22. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: An increasing concern in canada. *Canadian* 452 *respiratory journal* 2008;15(2):85-89.

453 23. Mummadi SR, Stoller JK, Lopez R, Kailasam K, Gillespie CT, Hahn PY. Epidemiology of adult 454 pleural disease in the united states. *Chest* 2021;160(4):1534-1551.

455 24. Søgaard M, Nielsen RB, Nørgaard M, Kornum JB, Schønheyder HC, Thomsen RW. Incidence, 456 length of stay, and prognosis of hospitalized patients with pleural empyema: A 15-year danish 457 nationwide cohort study. *Chest* 2014;145(1):189-192.

458 25. Arnold DT, Hamilton FW, Morris TT, Suri T, Morley A, Frost V, Vipond IB, Medford AR, Payne
459 RA, Muir P, et al. Epidemiology of pleural empyema in english hospitals and the impact of influenza.
460 *European Respiratory Journal* 2020:2003546.

461 26. Maguire D, Dunn P, McKenna H. How hospital activity in the nhs in england has changed 462 over time. 2016.

463 27. Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and
464 complicated pneumonias: Global trends in incidence, prevalence, and serotype epidemiology.
465 *European Journal of Clinical Microbiology & Infectious Diseases* 2014;33(6):879-910.

Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships
between invasive and carriage streptococcus pneumoniae and serotype- and clone-specific
differences in invasive disease potential. *The Journal of Infectious Diseases* 2003;187(9):1424-1432.

469 29. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Rückinger S, Dagan R, 470 Adegbola R, Cutts F, Johnson HL, et al. Association of serotype with risk of death due to 471 pneumococcal pneumonia: A meta-analysis. *Clinical Infectious Diseases* 2010;51(6):692-699.

472 30. Hyams C, Yuste J, Bax K, Camberlein E, Weiser JN, Brown JS. Streptococcus pneumoniae 473 resistance to complement-mediated immunity is dependent on the capsular serotype. *Infect Immun* 474 2010;78(2):716-725.

475 31. Kaushal N, Kumari S, Jhelum H, Sehgal D. In vitro and in vivo characterization of the 476 interaction, proinflammatory, immunomodulatory and antigenic properties of capsular 477 polysaccharide from streptococcus pneumoniae serotype 1. *International Journal of Biological* 478 *Macromolecules* 2020;143:521-532.

479 32. Bergman K, Härnqvist T, Backhaus E, Trollfors B, Dahl MS, Kolberg H, Ockborn G, Andersson 480 R, Karlsson J, Mellgren Å, et al. Invasive pneumococcal disease in persons with predisposing factors is 481 dominated by non-vaccine serotypes in southwest sweden. *BMC Infectious Diseases* 2021;21(1):756.

482 33. Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: Serotype 3 pneumococcal disease. 483 Frontiers in Cellular and Infection Microbiology 2020;10.

484 34. Pande A, Nasir S, Rueda AM, Matejowsky R, Ramos J, Doshi S, Kulkarni P, Musher DM. The
485 incidence of necrotizing changes in adults with pneumococcal pneumonia. *Clinical Infectious*486 *Diseases* 2012;54(1):10-16.

487 35. Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, von Gottberg A,
488 du Plessis M, Antonio M, Kwambana-Adams BA, et al. Global emergence and population dynamics of
489 divergent serotype 3 cc180 pneumococci. *PLOS Pathogens* 2018;14(11):e1007438.

490 36. Croucher NJ, Mitchell AM, Gould KA, Inverarity D, Barquist L, Feltwell T, Fookes MC, Harris 491 SR, Dordel J, Salter SJ, et al. Dominant role of nucleotide substitution in the diversification of 492 serotype 3 pneumococci over decades and during a single infection. *PLOS Genetics* 493 2013;9(10):e1003868.

494 37. Groves N, Sheppard CL, Litt D, Rose S, Silva A, Njoku N, Rodrigues S, Amin-Chowdhury Z, 495 Andrews N, Ladhani S, et al. Evolution of streptococcus pneumoniae serotype 3 in england and 496 wales: A major vaccine evader. *Genes* 2019;10(11).

497 38. Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO,
498 Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural
499 infection. *European Respiratory Journal* 2019:1900541.

500 39. White HD, Henry C, Stock EM, Arroliga AC, Ghamande S. Predicting long-term outcomes in 501 pleural infections. Rapid score for risk stratification. *Annals of the American Thoracic Society* 502 2015;12(9):1310-1316.

50340.Bintcliffe OJ, Hooper CE, Rider IJ, Finn RS, Morley AJ, Zahan-Evans N, Harvey JE, Skyrme-504Jones AP, Maskell NA. Unilateral pleural effusions with more than one apparent etiology. A505prospective observational study. Annals of the American Thoracic Society 2016;13(7):1050-1056.

506 41. Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, Marrie TJ, Singer DE, Coley CM, 507 Kapoor WN, Fine MJ. Do pulmonary radiographic findings at presentation predict mortality in 508 patients with community-acquired pneumonia? *Arch Intern Med* 1996;156(19):2206-2212.

509 42. Dean NC, Jones BE, Jones JP, Ferraro JP, Post HB, Aronsky D, Vines CG, Allen TL, Haug PJ. 510 Impact of an electronic clinical decision support tool for emergency department patients with 511 pneumonia. *Ann Emerg Med* 2015;66(5):511-520.

512 43. Federici S, Bédat B, Hayau J, Gonzalez M, Triponez F, Krueger T, Karenovics W, Perentes JY.
513 Outcome of parapneumonic empyema managed surgically or by fibrinolysis: A multicenter study.
514 Journal of Thoracic Disease 2021;13(11):6381-6389.

515 44. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. *Chest* 516 1997;111(6):1548-1551.

517 45. Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: Is

518 there evidence to make its use uncommon in clinical practice? *ERJ Open Research* 2020;6(1):00223-519 02019.

520

522 FIGURE LEGENDS

523 Figure 1: Study Cohort

- 524 Results from 3677 microbiology database occurrences of a positive blood or urine antigen
- 525 test were identified. There were 2657 cases of pneumococcal infection in adults, including
- 526 559 patients with parapneumonic effusions.

527 Figure 2: Vaccine group serotype trends in pneumococcal parapneumonic effusions in

528 Bristol, UK 2006-2018

- 529 (A) Incidence of pneumococcal parapneumonic effusion (per 100,000 adults), calculated
- using adult population data from the Office of National Statistics (Supplementary Data 4).
- 531 (B) proportion of serotyped disease caused by vaccine serotype group as shown from 2006-
- 532 18. Dashed lines show the introduction of paediatric PCV7 and PCV13.

533 Figure 3: 1-year survival in patients with pneumococcal parapneumonic effusions

- 534 (A) Kaplan-Meier survival curve and number at risk for patients with simple parapneumonic
- 535 effusion (SPE) (red line) and pleural infection (blue line). (B) Kaplan-Meier survival curve
- and number at risk for patients with pneumococcal pleural infection for low (red line),
- 537 medium (blue line) ad high (black line) RAPID score groups. The number of subjects at risk
- 538 immediately before each time point is listed in a numbers-at-risk table.

540 TABLES

541 Table 1: Clinical features of patients with pneumococcal parapneumonic effusions

Characteristic	All	SPE	Pleural infection	<i>P</i> value *	
	parapneumonic effusions (N=559)	(N=459)	(N=100)		
Microbiological Confirmation of	· · · · · · · · · · · · · · · · · · ·	(11-457)			
Blood culture	283 (51)	236 (51)	47 (47)	0.469	
Urinary antigen test	276 (49)	223 (49)	55 (55)	0.277	
Pleural Fluid Culture Results	270 (47)	223 (4))	55 (55)	0.277	
<i>S. pneumoniae</i> positive	42 (8)	0 (0)	42 (42)	<0.001	
Multi-organism positive	15 (3)	0 (0)	15 (15)	<0.001	
Demographics	15 (5)	0(0)	15 (15)	<0.001	
Male – N (%)	282 (50)	223 (49)	56 (56)	0.205	
Female – N (%)	277 (50)	236 (51)	44 (44)	0.205	
Age (years) – median (IQR)	68 (50-78)	69 (57-78)	55 (45-74)	<0.001	
Smoking Status - N (%)	00 (30-78)	0) (37-78)	55 (45-74)	<0.001	
Non-smoker	127 (23)	106 (23)	21 (21)	0.732	
Current smoker	127 (23)	100 (23)	46 (46)	0.732	
Ex-smoker	238 (43)			0.043	
	238 (43)	205 (45)	33 (33)	0.043	
Comorbidities – N (%)	0.15 (1.1)	001 (10)		0.051	
Chronic Lung Disease	245 (44)	201 (43)	44 (44)	0.856	
Cardiac Disease	304 (54)	261 (57)	43 (43)	0.011	
Upper GI/Swallow Problem	214 (38)	180 (40)	34 (34)	0.265	
Cerebrovascular Disease	39 (7)	29 (6)	10 (10)	0.148	
Type 2 Diabetes	95 (17)	79 (17)	16 (16)	0.809	
Chronic Liver Failure	25 (4)	21 (5)	4 (4)	0.672	
Intravenous Drug Usage	24 (4)	17 (4)	7 (7)	0.192	
Alcohol excess	53 (9)	38 (8)	15 (15)	0.028	
BMI ≤ 17 or BMI ≥ 35	23 (4)	16 (3)	7 (7)	0.056	
CURB65 Score on Admission			0.(0)		
0 N(%)	28 (5)	20 (4)	8 (8)	0.088	
1 N (%)	107 (19)	83 (18)	24 (24)	0.167	
2 N (%)	139 (25)	112 (24)	27 (27)	0.528	
3-5 N (%)	285 (51)	244 (53)	42 (42)	0.046	
Investigation Results – median (IC					
White cell count, $\times 10^{9}$ /L	17.8 (12.1-23.8)	17.0 (12.0-22.7)	20.8 (13.9-27.0)	0.005	
Neutrophil count, $\times 10^9/L$	14.9 (10.0-20.2)	14.2 (9.9-20.1)	18.5 (10.8-24.1)	0.003	
C-reactive protein, mg/dL	215 (133-341)	200 (129-312)	331 (213-412)	<0.001	
Albumin, g/L	30 (26-36)	31 (27-36)	29 (23-34.3)	0.666	
Urea, mmol/L	9.3 (6.4-13.2)	9.2 (6.5-13.3)	9.7 (6.1-12.8)	0.666	
Radiological features	100 (27)	100 (20)	10 (10)	0.001	
Bilateral effusion	139 (25)	129 (28)	10 (10)	0.001	
Outcomes - N (%)	100 (27)		00 (7.2)	0.000	
Acute renal failure †	198 (35)	170 (37)	28 (28)	0.088	
Liver dysfunction #	60 (11)	55 (12)	5 (5)	0.041	
ITU admission	110 (20)	92 (20)	18 (18)	0.649	
Increased care needed	198 (35)	176 (38)	22 (22)	0.002	
Admission days – median (IQR)	11 (6-20)	10 (5-20)	14 (10-21)	<0.001	
Mortality				0.70	
- Inpatient mortality	71 (13)	60 (13)	11 (11)	0.586	
- 30-day mortality	74 (13)	65 (14)	9 (9)	0.180	

- 90-day mortality	106 (19)	94 (21)	12 (12)	0.039
- 1-year mortality	150 (26)	134 (29)	16 (16)	0.008

542

543 * P-values represent the result of comparison between SPE and pleural infection groups with

either Fisher's exact test (categorical variables) or the Mann-Whitney U-test (non-parametric

545 continuous variables)

546 † Acute renal failure was defined as a reduction in renal function (as measured by creatinine

547 or eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury

548 # Liver dysfunction was defined as a transient disorder of hepatic function characterized by

549 either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute

550 liver failure may or may not be present, including jaundice, vomiting, coagulopathy,

551 hyperbilirubinemia, and increased serum lactate

Table 2: Clinical features of patients with serotype 1 and 3 pneumococcal

554 parapneumonic effusions

Characteristic	Serotype 1 N = 22	Serotype 3 N = 30	P value
Demographics – N (%)			
Male	13 (59)	16 (53)	0.181
Smoking			
- Current	11 (50)	11 (37)	0.353
- Ex-Smoker	5 (23)	12 (40)	0.201
Age – median (IQR)			
Age (years)	45 (40-69)	75 (62-83)	0.023
Comorbidities – N (%)			
Chronic Lung Disease	10 (46)	12 (40)	0.669
Cardiac Disease	9 (41)	21 (70)	0.038
Upper GI/Swallow Problem	3 (14)	13 (43)	0.027
Cerebrovascular Disease	3 (14)	5 (17)	0.771
Type 2 Diabetes	3 (14)	7 (23)	0.420
Chronic Liver Failure	0 (0)	2 (7)	0.210
Intravenous Drug Usage	1 (5)	1 (3)	0.714
Alcohol excess	2 (9)	4 (13)	0.656
Pleural Features – N (%)			
Pleural Infection	11 (50)	10 (33)	0.221
Loculation	5 (23)	3 (10)	0.205
Pus	4 (18)	6 (20)	0.858
RAPID Group			
- Low	10 (45)	4 (13)	0.011
- Medium	2 (9)	20 (67)	10.001
- High	8 (36)	5 (17)	0.024
Outcomes – N (%)			
Acute renal failure †	17 (77)	13 (43)	0.007
Liver dysfunction #	2 (9)	1 (3)	0.355
ITU admission	4 (18)	6 (20)	0.858
Increased care needed	6 (27)	10 (33)	0.646
30-day mortality	2 (9)	6 (20)	0.282
90-day mortality	3 (14)	11 (37)	0.068
365-day mortality	3 (14)	14 (47)	0.019
Admission days - median (IQR)	11 (5-21)	10 (4-18)	0.368

⁵⁵⁵ † Acute renal failure was defined as a reduction in renal function (measured by creatinine or
⁵⁵⁶ eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury
⁵⁵⁷ # Liver dysfunction was defined as a transient disorder of hepatic function characterized by
⁵⁵⁸ either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute
⁵⁵⁹ liver failure may or may not be present.

560 Table 3: Mortality among 100 Pneumococcal Pleural Infection cases with different

561 clinical features and RAPID severity Scores

562

	Pleural Infection			
Characteristic	Total Patients (N=100)	30 Day Mortality N (%)	90 Day Mortality N (%)	365 Day Mortality N (%)
Disease Characteristics				
Pus	59	0 (0)	0 (0)	1 (2)
No Pus	41	9 (22)	12 (29)	12 (29)
Loculation Present	49	8 (16)	10 (20)	12 (25)
No loculation Detected	51	1 (2)	2 (4)	5 (10)
Fibrinolytics used	33	4 (12)	6 (18)	11 (33)
Surgical Management *	29	0 (0)	0 (0)	0 (0)
- Loculation present	23	0 (0)	0 (0)	0 (0)
- No loculation	6	0 (0)	0 (0)	0 (0)
No Surgical Management	71	9 (13)	12 (17)	17 (24)
RAPID Risk Group				
Low	36	1 (3)	1 (3)	3 (8)
Medium	46	2 (4)	3 (7)	4 (9)
High	18	6 (33)	10 (55)	13 (72)

563

564 RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) Score 0-2 represents

565 low risk, 3-4 medium risk and 5-7 high risk

566

567 * 18 patients underwent surgery after fibrinolytic usage

568 Table 4: Cox Regression Analysis for risk factors in patients with pleural infection

569

Analysis	Fa	ctor	Beta (β) estimate	HR	95% CI	<i>P</i> -value
		Low	-	-	-	-
	RAPID Group	Medium	13.52	12.04	0.23-39.87	0.674
30-day mortality	r	High	28.51	19.33	0.55-92.33	0.638
	Age		-0.002	0.998	0.96-1.05	0.921
	Loculation		1.705	5.502	0.99-103	0.111
	RAPID Group	Low	-	-	-	-
		Medium	0.573	1.773	0.19-38.77	0.642
90-day mortality		High	2.709	15.01	1.24-40.06	0.049
	Age		0.015	1.02	0.97-1.07	0.550
	Loculation		1.582	4.86	1.27-31.87	0.043
	RAPID	Low	-	-	-	-
	Group Age	Medium	0.573	1.773	0.19-38.77	0.642
365-day mortality		High	2.709	15.01	1.24-40.06	0.049
	Age		0.027	1.028	0.99-1.07	0.188
	Loculation		1.041	2.836	1.04-9.00	0.050

570

571 Proportional hazard assumptions were tested by visual assessment of the KM survival curve,

572 log(-log) plots and Schoenfeld Residuals (Supplementary Data 7)







